XS
Xspray Pharma AB (publ)
XSPRAY.ST · STO
10.46 kr -3.86% (-0.42 kr)
1M +8.58%
Market Cap 515.9M kr
P/E Ratio -
Div. Yield -
ROE 26.00%
Bulios Fair Price
6.36 kr
39.2% downside
Current Price
10.46 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XSPRAY.ST is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.81x
EV/EBITDA N/A
P/S N/A
Growth
39 /100
Stable Book val. growth 2.83%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 26.00%
ROA 19.66%
Asset turnover 0.00x
Debt
61 /100
Moderate Current ratio 1.39x
Int. coverage -6.05x
Debt/Equity 0.23x
Stability
40 /100
Moderate EPS volatility 39.72%
Profitable years 0
Beta -0.03x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XSPRAY.ST
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Blake Leitch
Employees
24
Headquarters
Solna
Upcoming events
04 NOV
Earnings
Upcoming earnings report